Refine
Has Fulltext
- yes (12) (remove)
Is part of the Bibliography
- yes (12)
Document Type
- Journal article (12)
Language
- English (12)
Keywords
- Roux-en-Y gastric bypass surgery (3)
- obesity (3)
- bariatric surgery (2)
- endoluminal (2)
- negative pressure (2)
- vacuum-assisted closure (2)
- Brain μ-opioid receptors (1)
- COVID-19 (1)
- PCR (1)
- PET (1)
- PET imaging (1)
- Roux-en-Y gastric bypass (1)
- SARS-CoV-2 (1)
- Zucker fatty fa/fa rats (1)
- adiposity (1)
- anastomotic leak (1)
- anastomotic leakage (1)
- blood-nerve barrier (1)
- body mass index (BMI; kg/m\(^2\)) (1)
- brain plasticity (1)
- brown adipose tissue (1)
- caloric-restriction (1)
- elective surgery (1)
- endoscopic (1)
- energy homeostasis (1)
- esophageal perforation (1)
- fat appetite (1)
- fatty liver (1)
- gastric-bypass surgery (1)
- gastrointestinal perforation (1)
- glucose homeostasis (1)
- intestinal epithelial barrier (1)
- intestinal microbiota (1)
- intragastric balloon (1)
- laparoscopy (1)
- leptin (1)
- leptin system (1)
- lipodystrophy (1)
- magnetic resonance imaging (1)
- netrin-1 (1)
- neuropathic pain (1)
- noradrenaline (1)
- noradrenaline transporter (1)
- positron emission tomography imaging (1)
- radiotracer (1)
- screening (1)
- serotonin (1)
- serotonin transporter (1)
- sleeve gastrectomy (1)
- super-obesity (1)
- surgical complications (1)
- sympathetic nervous system (1)
- systemic endotoxemia (1)
- thermogenesis (1)
- tight junction proteins (1)
- type 2 diabetes (1)
- uncoupling protein 1 (1)
Background
Endoscopic vacuum therapy (EVT) is an effective treatment option for leakage of the upper gastrointestinal (UGI) tract. The aim of this study was to evaluate the clinical impact of quality improvements in EVT management on patients’ outcome.
Methods
All patients treated by EVT at our center during 2012–2021 were divided into two consecutive and equal-sized cohorts (period 1 vs. period 2). Over time several quality improvement strategies were implemented including the earlier diagnosis and EVT treatment and technical optimization of endoscopy. The primary endpoint was defined as the composite score MTL30 (mortality, transfer, length-of-stay > 30 days). Secondary endpoints included EVT efficacy, complications, in-hospital mortality, length-of-stay (LOS) and nutrition status at discharge.
Results
A total of 156 patients were analyzed. During the latter period the primary endpoint MTL30 decreased from 60.8 to 39.0% (P = .006). EVT efficacy increased from 80 to 91% (P = .049). Further, the need for additional procedures for leakage management decreased from 49.9 to 29.9% (P = .013) and reoperations became less frequent (38.0% vs.15.6%; P = .001). The duration of leakage therapy and LOS were shortened from 25 to 14 days (P = .003) and 38 days to 25 days (P = .006), respectively. Morbidity (as determined by the comprehensive complication index) decreased from 54.6 to 46.5 (P = .034). More patients could be discharged on oral nutrition (70.9% vs. 84.4%, P = .043).
Conclusions
Our experience confirms the efficacy of EVT for the successful management of UGI leakage. Our quality improvement analysis demonstrates significant changes in EVT management resulting in accelerated recovery, fewer complications and improved functional outcome.
Brain μ-opioid receptors (MORs) stimulate high-fat (HF) feeding and have been implicated in the distinct long term outcomes on body weight of bariatric surgery and dieting. Whether alterations in fat appetite specifically following these disparate weight loss interventions relate to changes in brain MOR signaling is unknown. To address this issue, diet-induced obese male rats underwent either Roux-en-Y gastric bypass (RYGB) or sham surgeries. Postoperatively, animals were placed on a two-choice diet consisting of low-fat (LF) and HF food and sham-operated rats were further split into ad libitum fed (Sham-LF/HF) and body weight-matched (Sham-BWM) to RYGB groups. An additional set of sham-operated rats always only on a LF diet (Sham-LF) served as lean controls, making four experimental groups in total. Corresponding to a stage of weight loss maintenance for RYGB rats, two-bottle fat preference tests in conjunction with small-animal positron emission tomography (PET) imaging studies with the selective MOR radioligand [\(^{11}\)C]carfentanil were performed. Brains were subsequently collected and MOR protein levels in the hypothalamus, striatum, prefrontal cortex and orbitofrontal cortex were analyzed by Western Blot. We found that only the RYGB group presented with intervention-specific changes: having markedly suppressed intake and preference for high concentration fat emulsions, a widespread reduction in [\(^{11}\)C]carfentanil binding potential (reflecting MOR availability) in various brain regions, and a downregulation of striatal and prefrontal MOR protein levels compared to the remaining groups. These findings suggest that the suppressed fat appetite caused by RYGB surgery is due to reduced brain MOR signaling, which may contribute to sustained weight loss unlike the case for dieting.